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Abstract
Copy number variations (CNVs) are a major cause of genetic disruption in the human genome with far more nucleotides
being altered by duplications and deletions than by single nucleotide polymorphisms (SNPs). In the multifaceted etiology of
autism spectrum disorders (ASDs), CNVs appear to contribute significantly to our understanding of the pathogenesis of this
complex disease. A unique resource of 42 extended ASD families was genotyped for over 1 million SNPs to detect CNVs that
may contribute to ASD susceptibility. Each family has at least one avuncular or cousin pair with ASD. Families were then
evaluated for co-segregation of CNVs in ASD patients. We identified a total of five deletions and seven duplications in
eleven families that co-segregated with ASD. Two of the CNVs overlap with regions on 7p21.3 and 15q24.1 that have been
previously reported in ASD individuals and two additional CNVs on 3p26.3 and 12q24.32 occur near regions associated with
schizophrenia. These findings provide further evidence for the involvement of ICA1 and NXPH1 on 7p21.3 in ASD
susceptibility and highlight novel ASD candidates, including CHL1, FGFBP3 and POUF41. These studies highlight the power
of using extended families for gene discovery in traits with a complex etiology.
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Introduction
Autism spectrum disorders (ASDs) encompass a range of
abnormal neurodevelopmental phenotypes characterized by a
core set of symptoms including social, communicative and
behavioral impairments [1]. The most recent prevalence studies
suggest that ASDs affect as many as 1 in 110 children [2–4]. While
ASD etiology is multifaceted, a significant portion is known to
stem from genetic causes given the increased concordance rate in
monozygotic twins (,91%) as compared to dizygotic twins
(,10%) [5–8]. Genetic studies over the past decade have
demonstrated that the underlying components are complex with
multiple genes acting either independently or perhaps synergisti-
cally to result in ASD phenotypes. While hundreds of candidate
genes have been published, linkage and association studies have
only recognized a small number of consensus regions [9].
Additionally, genome-wide association studies thus far have
identified very few regions that may contain a common genetic
cause, such as the regions on 5p14.1 and 5p15 [10–12]. Therefore,
it appears that rare and private variations may represent a
considerable portion of the genetic components involved in ASDs.
A growing number of studies have demonstrated the potential
contribution of copy number variations (CNVs) in the etiology of
many complex disorders including autism, Alzheimer’s disease,
epilepsy, and schizophrenia[13,14]. To date, CNVs believed to be
involved in ASDs occur at a relatively low frequency and are often
private, familial alterations, reflecting the genetic heterogeneity of
this disorder [15]. Furthermore, these alterations have implicated
a variety of genes within the glutamatergic, ubiquitin, and cell
adhesion pathways [16,17]. However, only a limited number of
findings have been replicated between research groups including
CNVs in CNTN4, NRXN1, 15q11-q13, 16p11.2, and 22q11.21
[17–20]. In addition, there appears to be variability in the clinical
consequences of CNVs. For instance, patients with CNVs on
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autism, developmental delay, intellectual disabilities and schizo-
phrenia [19,21–23]. Furthermore, there is evidence of phenotypic
heterogeneity within families carrying a 16p11.2 CNV including
siblings discordant for autism and transmission of a CNV from
asymptomatic parents [24,25]. This demonstrates that while a
CNV may provide a strong susceptibility to a phenotype, it may
act in concert with other genetic and environmental factors.
Several studies suggest that familial and sporadic cases of ASD
are genetically distinct. Extended, multiplex families are more
likely to carry heritable risk factors while, in contrast, sporadic
ASD families have demonstrated a higher rate of de novo CNVs
[26,27]. In this study, we examine 42 unique extended ASD
families and identify rare structural alterations that are shared
between multiple affected individuals. We hypothesized that that
we would unearth novel ASD susceptibility genes with a moderate
to strong effect by identifying CNVs that segregate in distantly
affected relatives. Intriguingly, many CNVs carriers, while not
being clinically diagnosed with an ASD, nonetheless present with a
history of psychiatric and developmental conditions. Our study
demonstrates the importance of decoding the various genetic
components involved in ASDs.
Materials and Methods
Ethics statement
We ascertained individuals at the John P. Hussman Institute for
Human Genomics (HIHG) at the University of Miami Miller
School of Medicine (Miami, Florida), the University of South
Carolina (Columbia, South Carolina), and the Center for Human
Genetics Research at Vanderbilt University (Nashville, Tennes-
see). Written informed consent was obtained from parents for all
minor children and those who were unable to give consent. In
addition, we obtained assent from all participants of the
appropriate developmental and chronological age. All participants
were ascertained using the protocol approved by the appropriate
Institutional Review Boards. Patients were collected for this study
for over a decade, with protocols and amendments being approved
at each stage. Oversight of the study at the University of Miami
falls under the UM Medical IRB B committee whose members
includes Ofelia Alvarez, M.D., Abdul Mian, Ph.D., Maria Alcaide,
M.D., Michelle Dunaj Lucking, J.D., Jean Jose, D.O., Howard
Landy, M.D., Bruce Nolan, M.D., FACP, FAASM, Emilio Weiss,
Pharm.D., and Cecilia Grano de Oro, B.A.
Ascertainment and sample description
Our dataset consisted of 410 individuals from 42 extended ASD
families. Extended families were defined as families with at least
two affected cousins. These families included either two (n=28),
three (n=8) or four (n=6) cousins or more distant relatives with
ASDs. We collected DNA from all affected and unaffected family
members wishing to participate.
ASD families were enrolled and recruited via support groups,
advertisements, and from clinical and educational settings. Core
inclusion criteria for ASD individuals were as follows: (1)
chronological age between 3 and 21 years of age, (2) a presumptive
clinical diagnosis of ASD, (3) an expert clinical determination of
ASD diagnosis using DSM-IV criteria supported by the Autism
Diagnostic Interview (ADI-R) [28,29], and (4) an IQ equivalent .
35 or developmental level .18 months as determined by the
Vineland Adaptive Behavior Scale (VABS) [30]. Diagnostic
determination was based on review by a panel consisting of
experienced clinical psychologists and a pediatric medical
geneticist. In those instances where an ADI-R was not available
(n=18), a best-estimate diagnosis was assigned using all available
clinical information including clinician summaries, a caregiver
report, and medical records. We excluded participants with severe
sensory problems (e.g., visual impairment or hearing loss),
significant motor impairments (e.g., failure to sit by 12 months
or walk by 24 months), or identified metabolic, genetic, or
progressive neurological disorders. Family history and pedigree
information was collected in a standard semi-structured interview
from a knowledgeable informant, most frequently the mother.
Additional clinical data were also collected by reviewing available
medical and psychiatric records of affected individuals.
Ancestry was identified by self-report and subsequently
confirmed by genotyping data plotted in EIGENSTRAT and
compared with HapMap populations [31,32]. One family, 7606,
was of African American descent and 41 families were of
European descent. Thirty-one families had only male ASD
individuals while the remaining eleven families had both male
and female affected individuals. Genomic DNA used for CNV
identification was purified from three different sources, whole
blood (n=276), saliva (n=8) and cell lines (n=126), using
Puregene chemistry on the Qiagen Autopure LS according to
standard protocols. Sample concentration was assessed via the
NanoDrop 8000 Spectrophotometer (Thermo Scientific) and all
samples were normalized to 50 ng/ul prior to genotyping.
Control individuals
Eight hundred and ninety-nine healthy children were recruited
by two centers. The first cohort was recruited by the Hussman
Institute for Human Genomics (HIHG) at the University of Miami
and included 565 children between the ages of 4 and 21 years.
Participants with developmental, behavioral, or neurological
conditions were excluded, as well as those with first degree
relatives with such disorders. We obtained consent from all
participants or, in the case of minors, their parents. Participants
meeting these criteria provided a saliva sample. A knowledgeable
informant, usually the mother, completed the Social Communi-
cation Questionnaire to screen for potential ASDs [33]. The
remaining 334 control individuals were part of a preterm birth
study from Nashville (Nashville Birth Cohort, NBC). These
samples were collected from the Centennial Medical Center in
Nashville, Tennessee from the cord blood of term pregnancies (.
37 weeks gestation) and were not screened for ASDs. All samples
were collected from live, singleton births delivered by mothers
between the ages of 18 and 40.
Race was identified in both control cohorts by parental self-
report and verified by comparing the genotyping data to HapMap
populations in EIGENSTRAT [31,32]. In rare cases of inconsis-
tency, the genetically determined ancestry was used. In total, 112
controls were classified as African American and 787 of European
descent.
Genotyping and copy number variation discovery
Genotyping of extended family members was performed with
either the Illumina Human 1Mv1_C BeadChip (n=349) or the
1M-DuoV3 BeadChip (n=61). Samples were processed using the
Infinium II assay. After genotyping, we carried out a series of
quality control (QC) tests. Reported and genetic sex were
examined using X-chromosome linked SNPs. Relatedness be-
tween samples and potential sample contaminations were
evaluated using genome-wide identity by descent and identity by
state estimation through genotyped SNPs in PLINK (http://pngu.
mgh.harvard.edu/,purcell/plink/ibdibs.shtml). We tested for
Mendelian inconsistencies for all SNPs in the WASP/PLATO
software (https://chgr.mc.vanderbilt.edu/plato). Samples with
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genotyping call rates below 95% were removed. All controls were
genotyped on the Human 1 M-DuoV3 BeadChips and underwent
the same QC steps as the family cohort with exception of testing
for Mendelian errors.
All subjects that passed QC were entered into the CNV analysis.
The CNV calls were generated via the PennCNV algorithm
(August 2009 version) using Log R ratio (LRR) and B allele
frequency [34]. Individual CNV calling was adjusted for intensity
wave artifacts (GC-waves) across the genome. A minimum of three
SNPs were used to define each CNV call. For members within
each family processed on the same chip, we were able to further
refine boundaries using the PennCNV trio/quartet-based calling
algorithm. Samples with a standard deviation of normalized
intensity (SDLRR) ,0.4 and not more than 300 detected CNVs
were included in the analysis. Samples with 0.3,SDLRR,0.4
and a number of detected CNVs between 100 and 300 (n=34)
were visually examined for mosaicism and extremely elevated
heterozygosity in BeadStudio V3 software. Due to hemizygosity in
males and X-chromosome inactivation in females, the CNV
analysis was restricted to autosomes. We used the Kruskal-Wallis
rank sum test to compare group specific CNV numbers.
Associations in contingency tables were determined using Fisher’s
exact test.
Identification of copy number variations concordant with
autism spectrum disorders
To identify CNVs that potentially contribute to ASD risk, we
performed a multi-step procedure of CNV filtering in the extended
families. First, we sought to recognize identical by descent variants
by screening for CNVs that segregate with all affected individuals
available for testing within the extended family. Next, we excluded
CNVs overrepresented in unaffected family members by filtering
out CNVs carried by more than one married-in unaffected
individual or unaffected child with no clear segregation with
affection status, since those CNVs likely segregate in affected
individuals by chance alone. To identify CNVs present in the
general population that are unlikely to contribute to ASDs, we
evaluated each region of interest to determine whether these areas
also contained CNVs in our 899 pediatric control samples as well
as the Database of Genomic Variants v9 (DGV, http://projects.
tcag.ca/variation/). For this assessment, we considered deletions
or duplications overlapping by at least 50% of their lengths as the
same CNV.
Validation by real-time PCR copy number assays
Predesigned TaqMan real-time polymerase chain reaction
(PCR) copy number assays (Applied Biosystems) were selected
within the CNVs chosen for validation using the GeneAssist
TM
Copy number Assay Workflow Builder (Table S1). Patients
carrying CNVs of interest as well as relatives negative for the
CNV were evaluated by real-time PCR. Each individual was
tested in quadruplicate according to standard protocols. Analysis
was performed in the CopyCaller Software v1.0 (Applied
Biosystems).
Results
Copy number variants identified
In total, 382 samples (97 ASD patients and 285 relatives without
a formal ASD diagnosis) were used in the final CNV analysis of the
families. Thirteen samples were excluded due to QC failure and
an additional fifteen samples were removed because their family
branches became uninformative. 838 pediatric control samples
survived QC and were also evaluated for CNVs.
Altogether, 23,263 autosomal CNVs at 5,653 distinct genomic
locations were identified in the 382 individuals comprising the
ASD family cohort. This includes 1,447 homozygous deletions
(6.2%), 14,212 single copy deletions (61.0%), 7,534 single copy
duplications (32.3%) and 170 homozygous duplications (0.7%).
CNVs were detected with an average size of 51.3 kilobases (kb).
We observed a difference in the average number of CNVs
between samples originating from different DNA sources (whole
blood, saliva, or lymphoblast cell line) as well as variation in
samples genotyped on each version of the Illumina BeadChips
(Table S2). The genotyping chip design contributes to this
variation because the number of sites used for CNV calling is
substantially greater on the Human 1 M-DuoV3 than on the
Human 1Mv1 C Beadchip (1,199,188 vs. 1,072,821). However,
since CNVs of interest were verified for transmission in family
members using real-time PCR, these observed differences did not
result in an increase of false positive findings in our study.
Copy number variants concordant with autism spectrum
disorders
To determine which CNVs may play a role in ASD risk, we
screened for CNVs segregating in all affected individuals within
each extended family. We hypothesized that these families would
carry a heterozygous genetic component that, while having a
moderate to strong influence on ASD, would exhibit incomplete
penetrance. We identified overlapping CNV segments shared by
every affected individual in each pedigree and examined the
transmission from the common ancestor to affected individuals,
excluding all recurrent CNVs that did not segregate with affection
status. This strategy reduced the initial thousands of copy number
variants to a manageable few given that first cousin share 12.5% of
their genetic information by chance alone and second cousins
share 3.125%.
Twelve CNVs of interest within eleven families of European
ancestry were identified and successfully validated using Taq-
Man real-time PCR copy number assays (Table 1, Figure S1).
Our findings include five deletions on 1p34.1, 2p24.2-p24.1,
6q11.1, 12q24.32, and 13q31.1 (Figure 1A–E), along with seven
duplications on 3p26.3, 4p16.3, 7p21.3, 10p12.31, 10q23.32,
15q11.2 and 15q24.1 (Figure 1F–K). Five of these CNVs at
7p21.3, 10p12.31, 10q23.32, 13q31.1 and 15q24.1 were not
identified in our control samples or in the publicly available
DGV database (Figure 2). The microduplications on 7p21.3
and 15q24.1 both segregate in the same four individuals in
family 17122 (Figure 1H). While these two duplications were
absent from our control dataset and the DGV, they each
overlap with ASD regions reported in the literature [35].
Further investigation into this family permitted us to refine the
breakpoints for both duplications and sequence the 7p21.3
breakpoints, thereby determining that this CNV was duplicated
in tandem [36].
Six of the twelve CNVs fall across the following known genes:
BTAF1, FGFPB3, ICA1, KHDRBS2, NXPH1, TNIP2, UBL7, and
ZSWIM5 (Table 1, Figure 2, Figure 3). The deletions on 1p34.1
and 6q11.1 are relatively small (2.7 and 12.8 kb) and located
within the intronic regions of ZSWIM5 and KHDRBS2, respec-
tively (Figure 3A,B). In contrast, the four duplications (4p16.3,
7p21.3, 10q 23.2, and 15q24.1) are, for the most part, larger
(11.0–352.4 kb) and either span whole genes, FGFPB3 and TNIP2,
or include exonic portions of BTAF1, ICA1, NXPH1, and UBL7
(Figure 3C–F).
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To investigate the potential inheritance models of putatively
pathogenic CNVs, we evaluated all available family history data
(Table S3). Each of the segregating CNVs were found in families
with only males affected, although a sister in family 17545 carries
the 1p34.1 deletion and was described as having developmental
delay and ASD symptoms (Figure 1A, individual 103, Table S3).
Five of the CNVs were transmitted maternally while the remaining
six were inherited both maternally and paternally. In every family,
the CNV passes through individuals without a formal ASD
diagnosis, supporting a dominant model of inheritance with
incomplete penetrance. Furthermore, the fact that some CNVs are
only transmitted maternally suggests possible parent of origin
effects.
For all family members negative for a diagnosis of ASD and
carrying a CNV of interest, half (19 of 38, 50.0%) have a history of
psychiatric or developmental conditions, including ASD symptoms
without a formal diagnosis, alcoholism, anxiety disorder, attention
deficit and hyperactivity disorder (ADHD), bipolar disorder, major
or postpartum depression, obsessive compulsive disorder, opposi-
tional defiant disorder (ODD), and speech disorders. The
complete clinical information for these individuals is shown in
Table S3. To determine whether CNV carriers had an increased
frequency of psychiatric or developmental disorders, we compared
the clinical features of twenty CNV carriers to their spouses who
did not carry the CNV (individuals specified on Table S3). Twelve
of the CNV carriers were found to have one of the clinical
diagnoses listed above, while only six of their spouses were
diagnosed with one of the above features. When measured by
Fisher’s exact test, this difference trended towards but did not
reach significance (p=0.111). While we believe that the CNVs of
interest may confer risk for ASD, our data also suggest that these
CNVs may play a more general role in a range of other
neuropsychiatric conditions.
Discussion
Using a unique resource of ASD extended families, twelve loci
were found that co-segregate with disease and may be involved in
ASD susceptibility. In evaluating the potential pathogenicity of
each region, we first prioritized rare structural variants not
identified in controls, then proven ASD regions and genomic areas
linked to neuropsychiatric disease, and, lastly, on CNVs containing
genes with a known, neuronal function (Figure 2). Of the twelve
structural variants identified, seven were observed at a low
frequency in our control and the DGV datasets and two additional
CNVs overlap with those identified in the literature, leaving three
novel CNVs unique to our ASD families (Figure 2). Two CNVs
fall within regions previously linked to ASD, while five more are
appealing candidates due to their locations mapping across or near
regions either correlated with neuropsychiatric disease or contain-
ing genes related to neuronal processes. Three of the duplications
(3p26.3, 7p21.3 and 15q24) also provide further support for the
hypothesis that the ubiquitin and cell adhesion pathways are
involved in ASD risk [17].
Previous evidence from ASD families intersects with two of the
structural variants that we identified: 7p21.3 and 15q24.1. On
7p21.3, duplications of approximately the same size and location
have been reported in two additional ASD families [35]. The
duplications in all three ASD families fall across ICA1 (islet cell
autoantigen 1) and NXPH1 (neurexophilin 1), both appealing candidate
genes. Interestingly, ICA1 localizes to dendrites and plays a role in
glutamatergic signaling [37]. Furthermore, the NXPH1 interacts
with neurexin Ia, a protein that promotes adhesion between






















del 1p34.1 chr1:45408389–45411073 2,684 17545 ZSWIM5 0.012 [8/1] 0.027 [3/0] 4
2p24.2–p24.1 chr2:19065745–19100096 34,351 7745 OSR1 005
6q11.1 chr6:62507037–62519883 12,846 17342 KHDRBS2 002
12q24.32 chr12:125875006–125881162 6,156 17678 LOC100128554 0.007 [1/4] 0 18
13q31.1 chr13:77912491–77917728 5,237 17142 POU4F1 000
dup 3p26.3 chr3:57010–103697 46,687 37994 CHL1 0.003 [2/0] 0 5




352,411 17122 ICA1, NXPH1 000
10p12.31 chr10:21727129–21818381 91,252 37232 C10orf114 000
10q23.32 chr10:93621936–93730409 108,473 37425 BTAF1, FGFBP3
{ 000
15q11.2 chr15:18411624–18472812 61,188 17668 GOLGA6L6 0.004 [3/0] 0.009 [0/1] .300
15q24.1 chr15:72538187–72549215
ˆ ˆ ˆ
11,028 17122 UBL7 000
ˆCNV boundaries correspond to the minimal size detected by Illumina’s 1M genotyping array.
ˆˆCNV boundaries sequenced in Cukier, et al, 2011.
ˆˆˆCNV boundaries correspond to the minimal size refined in Cukier, et al, 2011.
*CNV type reported in controls corresponds to the CNV type (del or dup) identified in ASD extended families.
Genes in bold fall within the CNV.
{Whole gene duplication.
HIHG - University of Miami Hussman Institute for Human Genomics control cohort.
NBC - Nashville Birth Cohort.
DGV - Database of Genomic Variants.
doi:10.1371/journal.pone.0026049.t001
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26049Figure 1. Copy number variations identified in 11 families. A–E) Five extended ASD families had deletions segregating with disease. F–K) Six
ASD families carried duplications that segregated with ASD. Family 17122 had two duplications that were inherited in an identical manner (H). Only
individuals marked with a small circle had DNA available for testing.
doi:10.1371/journal.pone.0026049.g001
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autism patients [38,39]. The duplication on chromosome 15q24.1
falls within the 1.33 Mb critical region of a previously reported
microdeletion and microduplication syndrome found in patients
with autistic features, delayed development and mental retardation
[36,40,41]. At approximately 10 kb, this CNV is much smaller
than those previously reported in the region and only falls across a
single gene, UBL7 (ubiquitin-like 7) [36]. While UBL7 is expressed in
the brain, little is currently known about its specific function [42].
Three additional loci we identified occur near areas connected
to other neuropsychiatric diseases: 3p26.3, 4p16.3 and 12q24.32.
Regions on 3p26.3 and 12q24.32 have each been implicated in
schizophrenia, with 3p26.3 also being connected to intellectual
disability [43–45]. While the 3p26.3 microduplication does not
Figure 3. Copy number variations that intersect genes. A,B) Deletions on 1p34.1 and 6q11.1 fall within the intronic regions of ZSWIM5 and
KHDRBS2, respectively. C–F) Four duplications on 4p16.3, 7p21.3, 10q 23.2, and 15q24.1 completely encompass the FGFPB3 and TNIP2 genes and
traverse portions of BTAF1, ICA1, NXPH1, and UBL7. Deletions are denoted with red bars, duplications marked by green bars and genes are annotated
with blue lines. Genes that intersect CNVs are in bold.
doi:10.1371/journal.pone.0026049.g003
Figure 2. Prioritization of copy number variations of interest. Structural variants were first assessed to determine whether they were present
in our control individuals or the Database of Genomic Variants. Literature searches were then performed to determine if the CNVs we identified were
previously reported as ASD regions with similar breakpoints or overlay with larger ASD reported regions. Higher priority was given to variation absent
in controls and those that fell within regions previously connected to ASDs. Low frequency CNVs were identified in our control HIHG and NBC
dataset, but at a frequency below 1.5%. Duplications are in green and deletions are in red.
doi:10.1371/journal.pone.0026049.g002
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molecule with homology to L1CAM), an intriguing ASD candidate
gene. CHL1 has increased expression in presynaptic terminals and
acts to regulate SNARE complexes [46]. Lastly, the 4p16.3 region
has been connected to developmental delay, mental retardation,
Huntington’s disease and Wolf-Hirchhorn syndrome [47,48]. The
variety of features reported in patients carrying CNVs within each
region, combined with the pattern of transmission within our
families, may demonstrate a variability in penetrance and clinical
presentations, possibly in a gender specific manner. For example,
there are four male ASD individuals in family 7663 who carry a
4p16.3 duplication, but all six family members with the
duplication (individuals 001, 100, 132, 134, 1001, and 1017) were
reported to have either a speech or language problem as a child
(Table 1, Figure 1G).
The novel 10q23.32 microduplication encompasses a strong
ASD candidate, the fibroblast growth factor binding protein 3 (FGFBP3)
gene. FGFBP3 is expressed in fetal brain and binds to the FGFs,
which are required throughout brain development, neuronal
differentiation and survival [49,50]. Notably, a transgenic mouse
model of a related FGF gene, FGFR1, mimics physiological
features of schizophrenia such as increased levels of dopamine and
sensory impairment [51,52].
One last intriguing CNV is the novel deletion on 13q31.1. This
deletion does not contain a gene, but is located 153.5 kb upstream of
thePOUdomain,class4,transcriptionfactor1(POU4F1)gene,alsoknown
as BRN3A, an appealing ASD candidate. POU4F1 plays a role in
neuronal development and differentiation through careful timed
repression of non-neuronal genes [53,54]. The 13q31.1 deletion,
while not disrupting POU4F1 directly, may affect the regulation of
developmental timing or tissue specific regulation of this gene.
Our approach of using extended ASD families successfully
identified rare variants that may be associated with ASD on
7p21.3 and 15q24.1, as well as structural aberrations near regions
related to other neuropsychiatric disorders on 3p26.3, 4p16.3 and
12q24.32. These results demonstrate that rare, heritable CNVs
play a significant role in ASD etiology. Our findings support the
hypothesis that altering the dosage of a gene or its regulatory
elements can lead to a severe clinical consequence and brings us
one step closer to deciphering the genetic heterogeneity of autism
spectrum disorders.
Supporting Information
Figure S1 Validation of copy number variations by real-
time PCR. A-K) Results for one assay at each genomic location
that was validated. The X axis marks the individual within each
family and the Y-axis shows the number of copies. The normal
copy number is always two. For those families carrying deletions
(A–E), individuals with a copy number of one were confirmed to
carry the deletion. For families with duplications (F–G), a copy
number of three identifies those individuals with the increase in
copy number. Family 17122 (H) shows one assay for each of the
duplications it carries on 7p21.3 and 15q24.
(PDF)
Table S1 TaqMan Real-Time PCR Copy Number
Assays. At least one copy number variation assay was selected
to validate each genomic region.
(XLSX)
Table S2 Number Variations identified in Autism
Spectrum Disorder Family Cohort and Control Individ-
uals. Summary of the number of variations identified, with case
and control samples divided by DNA source (blood, cell lines, or
saliva) and the type of Illumina SNP array chip used (either version
1Mv1_C or 1M-DuoV3).
(XLSX)
Table S3 Clinical Information for Families with Vali-
dated Copy Number Variations. This table provides
phenotype information for all family members evaluated, with
emphasis on ASD symptoms and developmental and neuropsy-
chiatric diagnoses. Deletions and then duplications are listed,
organized by chromosomal location.
(XLSX)
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